Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Analgesics
ROXRO PHARMA Completes $42.7 Million Financing Round
June 26th, 2007
ROXRO PHARMA, Inc. said today it has completed a private placement financing, raising a total of $42.7 million to support continued development of the company's novel pain compounds, including its lead analgesic ROX-888. The financing was led by the venture capital firms Prospect Venture Partners and Sutter Hill Ventures, both of Palo Alto, CA. Also participating in private placement was Thomas Weisel Healthcare Venture Partners of Palo Alto. This completes the company's second round of financing, which began in late 2005. Earlier this month ROXRO announced it has completed the Phase 3 clinical trials program for ROX-888, its novel intranasal pain...
Source: Drug Law Weekly (2007-06-26)
|
